Table q1_q4_2020_prescription_drugs_wac

Table: q1_q4_2020_prescription_drugs_wac_increases , manufacturer_name like G*

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000260	Galderma Laboratories	06/30/2020	00299590645	Epiduo?Forte Gel 0.1% / 2.5% Pump 45GM (Adapalene and Benzoyl Peroxide) 3 mg/g, 25 mg/g	06/05/2020	27.20	581.45	03/12/2013	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Drug developed by Galderma
Rx0000260	Galderma Laboratories	06/30/2020	00299590660	Epiduo?Forte Gel 0.1% / 2.5% Pump 60GM (Adapalene and Benzoyl Peroxide) 3 mg/g, 25 mg/g	06/05/2020	36.25	775.30	03/12/2023	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Drug developed by Galderma
Rx0000260	Galderma Laboratories	06/30/2020	00299598030	Mirvaso? Topical Gel 0.33% 30GM (Brimonidine) 5 mg/g	06/05/2020	24.60	525.75	06/13/2031	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Drug developed by Galderma
Rx0000260	Galderma Laboratories	06/30/2020	00299598035	Mirvaso? Topical Gel 0.33% 30GM PUMP (Brimonidine) 5 mg/g	06/05/2020	24.60	525.75	06/13/2031	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Drug developed by Galderma
Rx0000260	Galderma Laboratories	06/30/2020	00299382230	Oracea? Capsules 40MG (Doxycycline, USP) 40 mg/1	06/05/2020	36.25	775.20	12/19/2027	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Drug purchased by Galderma more than five years ago
Rx0000260	Galderma Laboratories	06/30/2020	00299382330	Soolantra? Cream 1% 30GM (Ivermectin) 10 mg/g	06/05/2020	36.70	401.65	03/13/2034	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Drug developed by Galderma
Rx0000260	Galderma Laboratories	06/30/2020	00299382345	Soolantra? Cream 1% 45GM (Ivermectin) 10 mg/g	06/05/2020	28.15	602.45	03/13/2034	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Drug developed by Galderma
Rx0000087	Gilead Sciences, Inc.	03/31/2020	61958200201	DESCOVY (emtricitabine 200mg/tenofovir alafenamide 25mg) tablets, 30ct bottle	01/01/2020	84.38	1842.28	08/15/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2020	61958190101	GENVOYA (elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg) tablets, 30ct bottle	01/01/2020	148.32	3238.31	10/04/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2020	61958050101	HEPSERA (adefovir dipivoxil 10mg) tablets, 30ct bottle	01/01/2020	71.25	1555.60	07/23/2018	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2020	61958210101	ODEFSEY (emtricitabine 200mg/rilpivirine 25mg/tenofovir alafenamide 25mg) tablets, 30ct bottle	01/01/2020	134.98	2947.11	08/15/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2020	61958070301	TRUVADA (emtricitabine 100mg/tenofovir disoproxil fumarate 150mg) tablets, 30ct bottle	01/01/2020	84.38	1842.28	09/09/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2020	61958070401	TRUVADA (emtricitabine 133mg/tenofovir disoproxil fumarate 200mg) tablets, 30ct bottle	01/01/2020	84.38	1842.28	09/09/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2020	61958070501	TRUVADA (emtricitabine 167mg/tenofovir disoproxil fumarate 250mg) tablets, 30ct bottle	01/01/2020	84.38	1842.28	09/09/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2020	61958070101	TRUVADA (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) tablets, 30ct bottle	01/01/2020	84.38	1842.28	01/13/2024	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2020	61958140101	TYBOST (cobicistat 150mg) tablets, 30ct bottle	01/01/2020	11.07	241.73	09/03/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2020	61958230101	VEMLIDY (tenofovir alafenamide 25mg) tablets, 30ct bottle	01/01/2020	53.71	1172.59	08/15/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2020	61958040401	VIREAD (tenofovir disoproxil fumarate 150mg) tablets, 30ct bottle	01/01/2020	53.21	1161.71	07/25/2018	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2020	61958040501	VIREAD (tenofovir disoproxil fumarate 200mg) tablets, 30ct bottle	01/01/2020	53.21	1161.71	07/25/2018	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2020	61958040601	VIREAD (tenofovir disoproxil fumarate 250mg) tablets, 30ct bottle	01/01/2020	53.21	1161.71	07/25/2018	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2020	61958040101	VIREAD (tenofovir disoproxil fumarate 300mg) tablets, 30ct bottle	01/01/2020	57.41	1253.50	07/25/2018	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2020	61958040301	VIREAD (tenofovir disoproxil fumarate 40mg/scoop) oral powder, 60g	01/01/2020	31.30	683.48	07/25/2018	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000088	Gilead Sciences, LLC	03/31/2020	15584010101	ATRIPLA (efavirenz 600mg/emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) tablets, 30ct bottle	01/01/2020	137.16	2994.71	04/28/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.